Long-term tumor control after Gamma Knife radiosurgery for sporadic vestibular schwannoma

医学 放射外科 神经鞘瘤 桥小脑角 前庭系统 听神经瘤 面神经 放射科 外科 神经瘤 原发性肿瘤 中枢神经系统疾病 前庭神经鞘瘤 颅神经疾病 前庭神经 伽玛刀 挽救疗法 核医学 回顾性队列研究 肿瘤进展
作者
John P. Marinelli,Ghazal S. Daher,Karl R. Khandalavala,Eric E. Babajanian,James R. Dornhoffer,Christine M. Lohse,Bruce E. Pollock,Paul D. Brown,Jamie J. Van Gompel,María Peris Celda,Brian A. Neff,Kanthaiah Koka,Matthew L. Carlson,Michael J. Link
出处
期刊:Journal of Neurosurgery [American Association of Neurological Surgeons]
卷期号:: 1-7
标识
DOI:10.3171/2025.8.jns25829
摘要

OBJECTIVE The objective of this study was to describe the long-term efficacy of single-fraction stereotactic radiosurgery (SRS) for the primary treatment of sporadic vestibular schwannoma. METHODS Adult (≥ 18 years of age) patients with sporadic vestibular schwannoma who underwent SRS from 2000 through 2022 were included. RESULTS A total of 749 patients met inclusion criteria, the majority (n = 566, 76%) of whom had tumors extending into the cerebellopontine angle at SRS. The median patient age at SRS was 62 years, half (50%) of the patients were women, and 744 (99%) exhibited House-Brackmann grade I facial nerve function at SRS. A total of 42 patients experienced radiosurgical failure and underwent salvage treatment; the median duration of follow-up for the patients who did not undergo salvage treatment was 7.0 years. Overall tumor control rates (95% CI, number still at risk) at 1, 3, 5, 10, and 15 years after SRS were 100% (100%–100%, 718), 98% (97%–99%, 589), 96% (94%–97%, 464), 92% (90%–95%, 258), and 91% (89%–94%, 125), respectively. Patient age (hazard ratio [HR] for a 10-year increase of 0.92, 95% CI 0.71–1.19; p = 0.5), presence of a macrocystic tumor (HR 0.59, 95% CI 0.14–2.46; p = 0.5), and treated tumor volume (HR for a 1-cm 3 increase of 1.02, 95% CI 0.88–1.18; p = 0.8) were not significantly associated with the risk of salvage. Three distinct post-SRS tumor behavior patterns were observed, with 13% of patients demonstrating tumor pseudoprogression, all but 4 of whom demonstrated pseudoprogression by year 5 post-SRS. CONCLUSIONS SRS demonstrates durable tumor control through 15 years of follow-up in most patients (91%); however, a minority are found to still experience SRS failure even beyond 10 years of surveillance. Although occurring in only a minority of patients, tumor pseudoprogression can be evident out to 5 years or longer post-SRS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hooqueen完成签到 ,获得积分10
1秒前
烟花的应助被Andrew采纳,获得10
2秒前
伶俐晓博完成签到 ,获得积分10
2秒前
木鱼完成签到,获得积分10
3秒前
小二郎的应助被lin采纳,获得10
4秒前
木鱼发布了新的文献求助10
5秒前
Cyan完成签到 ,获得积分10
8秒前
guhao完成签到 ,获得积分10
10秒前
ZHANG完成签到 ,获得积分10
12秒前
cjhsci发布了新的文献求助10
12秒前
可爱紫文完成签到 ,获得积分10
15秒前
研友_8WMgOn完成签到 ,获得积分10
18秒前
shuguolei发布了新的文献求助10
20秒前
称心忆灵完成签到,获得积分10
21秒前
cjhsci发布了新的文献求助10
32秒前
33秒前
Andrew发布了新的文献求助10
38秒前
Canmiyo完成签到 ,获得积分10
38秒前
牛马完成签到,获得积分10
38秒前
左丘映易完成签到,获得积分10
39秒前
qpzn完成签到,获得积分10
43秒前
cjhsci发布了新的文献求助10
46秒前
饭遇碟完成签到 ,获得积分10
48秒前
yunsww完成签到,获得积分10
50秒前
281911480完成签到,获得积分10
53秒前
笛卡尔的情书完成签到 ,获得积分10
54秒前
世界是自己挣的完成签到 ,获得积分10
55秒前
糖宝完成签到 ,获得积分0
57秒前
稳重的秋天完成签到,获得积分10
57秒前
shuguolei完成签到,获得积分10
1分钟前
1分钟前
完美飞凤完成签到,获得积分10
1分钟前
孙新雨完成签到 ,获得积分10
1分钟前
冷艳的寒天完成签到 ,获得积分10
1分钟前
小路完成签到,获得积分10
1分钟前
cjhsci发布了新的文献求助10
1分钟前
oxygen完成签到 ,获得积分10
1分钟前
AmyHu完成签到,获得积分10
1分钟前
孑然完成签到 ,获得积分10
1分钟前
晃悠悠的可乐完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Aspects of Post-SPE Phonology 2000
CODESSA 2000
Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals 888
Rosenblum, Global Change Biology 800
Holistic Discourse Analysis, Second Edition by Robert E. Longacre (2012-09-10) 666
Berberine regulates the TLR4 signaling pathway to suppress hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells 530
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 物理 有机化学 化学工程 内科学 生物化学 复合材料 催化作用 心理学 细胞生物学 无机化学 电极 光电子学 人工智能
热门帖子
关注 科研通微信公众号,转发送积分 7858334
求助须知:如何正确求助?哪些是违规求助? 9376452
关于积分的说明 20703989
捐赠科研通 7457014
什么是DOI,文献DOI怎么找? 3346452
关于科研通互助平台的介绍 2488760
邀请新用户注册赠送积分活动 2370717